Literature DB >> 15555642

Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance.

Frank G Boess1, Martin Hendrix, Franz-Josef van der Staay, Christina Erb, Rudy Schreiber, Wilma van Staveren, Jan de Vente, Jos Prickaerts, Arjan Blokland, Gerhard Koenig.   

Abstract

An essential element of the signalling cascade leading to synaptic plasticity is the intracellular second messenger molecule guanosine 3',5'-cyclic monophosphate (cGMP). Using the novel, potent, and selective inhibitor Bay 60-7550, we show that the enzyme 3',5'-cyclic nucleotide phosphodiesterase type 2 (PDE2) is responsible for the degradation of newly synthesized cGMP in cultured neurons and hippocampal slices. Inhibition of PDE2 enhanced long-term potentiation of synaptic transmission without altering basal synaptic transmission. Inhibition of PDE2 also improved the performance of rats in social and object recognition memory tasks, and reversed MK801-induced deficits in spontaneous alternation in mice in a T-maze. Our data provide strong evidence that inhibition of PDE2 can improve memory functions by enhancing neuronal plasticity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15555642     DOI: 10.1016/j.neuropharm.2004.07.040

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  90 in total

Review 1.  Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.

Authors:  Thérèse Keravis; Claire Lugnier
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 2.  Phosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatment.

Authors:  Isaac Levy; Anelia Horvath; Monalisa Azevedo; Rodrigo Bertollo de Alexandre; Constantine A Stratakis
Journal:  Curr Opin Pharmacol       Date:  2011-10-31       Impact factor: 5.547

3.  Computational determination of binding structures and free energies of phosphodiesterase-2 with benzo[1,4]diazepin-2-one derivatives.

Authors:  Bo Yang; Adel Hamza; Guangju Chen; Yan Wang; Chang-Guo Zhan
Journal:  J Phys Chem B       Date:  2010-11-15       Impact factor: 2.991

4.  Interaction between phosphodiesterases in the regulation of the cardiac β-adrenergic pathway.

Authors:  Claire Y Zhao; Joseph L Greenstein; Raimond L Winslow
Journal:  J Mol Cell Cardiol       Date:  2015-09-23       Impact factor: 5.000

5.  Phosphodiesterase 2A as a therapeutic target to restore cardiac neurotransmission during sympathetic hyperactivity.

Authors:  Kun Liu; Dan Li; Guoliang Hao; David McCaffary; Oliver Neely; Lavinia Woodward; Demetris Ioannides; Chieh-Ju Lu; Marcella Brescia; Manuela Zaccolo; Harikrishna Tandri; Olujimi A Ajijola; Jeffrey L Ardell; Kalyanam Shivkumar; David J Paterson
Journal:  JCI Insight       Date:  2018-05-03

6.  Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes.

Authors:  Liliana R V Castro; Ignacio Verde; Dermot M F Cooper; Rodolphe Fischmeister
Journal:  Circulation       Date:  2006-05-01       Impact factor: 29.690

7.  Improved long-term memory via enhancing cGMP-PKG signaling requires cAMP-PKA signaling.

Authors:  Eva Bollen; Daniela Puzzo; Kris Rutten; Lucia Privitera; Jochen De Vry; Tim Vanmierlo; Gunter Kenis; Agostino Palmeri; Rudi D'Hooge; Detlef Balschun; Harry M W Steinbusch; Arjan Blokland; Jos Prickaerts
Journal:  Neuropsychopharmacology       Date:  2014-05-12       Impact factor: 7.853

8.  Efficacy of B-Type Natriuretic Peptide Is Coupled to Phosphodiesterase 2A in Cardiac Sympathetic Neurons.

Authors:  Dan Li; Chieh-Ju Lu; Guoliang Hao; Hannah Wright; Lavinia Woodward; Kun Liu; Elisa Vergari; Nicoletta C Surdo; Neil Herring; Manuela Zaccolo; David J Paterson
Journal:  Hypertension       Date:  2015-04-27       Impact factor: 10.190

9.  Reversal of oxidative stress-induced anxiety by inhibition of phosphodiesterase-2 in mice.

Authors:  Anbrin Masood; Ahmed Nadeem; S Jamal Mustafa; James M O'Donnell
Journal:  J Pharmacol Exp Ther       Date:  2008-05-02       Impact factor: 4.030

Review 10.  The role of phosphodiesterases in schizophrenia : therapeutic implications.

Authors:  Judith A Siuciak
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.